Sernova Biotherapeutics Appoints New Interim Chair
In an exciting development for Sernova Biotherapeutics, a pioneer in regenerative medicine based in Canada and the United States, Jonathan Rigby, who is also the Chief Executive Officer, has been appointed as the Interim Chair of the board of directors. This decision comes as part of the company’s ongoing commitment to advancing its innovative Cell Pouch technology aimed at addressing type 1 diabetes (T1D). Jonathan Rigby's appointment is effective immediately, and he will serve in this role until a suitable independent director is named as the new Chair.
Strategic Initiatives and Financing Discussions
As Sernova moves forward, the company is actively engaged in discussions about potential investment partnerships. This includes promising talks with GoldTrack Ventures and the Kingdom of Saudi Arabia, aiming to secure crucial financing that could significantly enhance Sernova's capacity to innovate and deliver solutions for those living with T1D.
Jonathan Rigby expressed optimism regarding the company's current trajectory, stating, "Sernova is making significant strides on multiple strategic and operational fronts. The recent release of encouraging clinical data, formation of a world-class Clinical Advisory Board, and active investment discussions with multiple parties is encouraging." His focus remains on delivering a functional cure for type 1 diabetes, enhancing the company’s long-term shareholder value.
Recent Changes in Leadership
In conjunction with Mr. Rigby’s new role, Sernova also announced the departure of its Chief Business Officer, Modestus Obochi. The company extends its gratitude to Dr. Obochi for his leadership during his time with Sernova. Such leadership transitions are crucial as they align with the company's strategy to bolster its capabilities in both operational and research dimensions.
Innovation in Regenerative Medicine
Sernova Biotherapeutics is at the forefront of developing regenerative medicine therapeutics, particularly through its innovative Cell Pouch technology. This technology involves partnerships with human donor cells or stem-cell derived islet-like clusters, which aim to create Bio-hybrid Organs. These organs integrate non-biomaterials, like the Cell Pouch, with living tissues designed to restore or enhance organ functions. Sernova’s pioneering solutions are focused initially on T1D, but also include application in thyroid disorders, potentially offering revolutionary treatment pathways for patients facing chronic health issues.
Company Contact Information
For those seeking further information about Sernova Biotherapeutics or its innovative projects, inquiries can be directed to:
David Burke
VP, Investor Relations
(917) 751-5713
Email: David.Burke@sernova.com
Website: sernova.com
Frequently Asked Questions
What is the role of Jonathan Rigby at Sernova?
Jonathan Rigby serves as the Chief Executive Officer and has now taken on the role of Interim Chair of the board of directors.
What is the focus of Sernova Biotherapeutics?
Sernova Biotherapeutics specializes in developing regenerative medicine aimed at creating Bio-hybrid Organs, particularly for treating type 1 diabetes.
Who else is involved in Sernova's strategic initiatives?
The company is engaged in discussions with investment partners including GoldTrack Ventures and the Kingdom of Saudi Arabia.
What innovative technology is Sernova developing?
Sernova is developing its Cell Pouch technology, which aims to integrate living tissues with synthetic materials to create effective treatments for chronic diseases.
How can I learn more about Sernova?
To learn more, you can contact David Burke, VP of Investor Relations, or visit Sernova's official website for the latest updates and information.
